rpoB変異性Clostridioides difficile感染に対するフィダキソミシンのin vivo有効性
Mai Thu Hoai1, Yutaro Hitomi2, Tsutomu Fujii3
1Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan; Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Anaerobe
|September 5, 2025
まとめ
フィダキソミシンは,rpoB変異がある場合でも,Clostridioides difficile感染 (CDI) を効果的に治療します. CDIにおける抗生物質耐性に対する継続的な監視は,効果的な治療戦略に不可欠です.
科学分野:
- 微生物学
- 感染症
- 薬理学について
背景:
- クロストリディオイドス・ディフィシル感染 (CDI) は,医療関連の重要な下痢疾患である.
- RNAポリメラーゼ阻害剤であるフィダキソミシンは,CDI治療の主要な抗生物質です.
- C. difficileの新たなrpoB変異はフィダキソミシンに対する感受性を低下させる可能性があります.
研究 の 目的:
- rpoB変異がC. difficileの毒性に対するインビボの影響を評価する.
- CDIモデルでC. difficile rpoB変異株に対するフィダキソミシンの有効性を評価する.
主な方法:
- フィダキソミシンの感受性が低下したrpoB変異株 (C. difficile G1073R-2024) の生成
- ネズミのCDIモデルにおける変異株と親株の毒性と治療反応の比較
- 生存率,体重,臨床スコア,糞便の細菌負荷の評価
主要な成果:
- rpoB変異体はアミノ酸変異 (Gln1073Arg) とフィダキソミシンMIC (128μg/ mL) の増加を示した.
- 変異株と親株の間では,体内毒性の有意な違いは観察されなかった.
- フィダキソミシンによる治療では,100%の生存率と,両種の細菌の比重の減少が達成されました.
結論:
- フィダキソミシンは,rpoB変異を有するC. difficile菌株によって引き起こされるCDIに対して有効である.
- この研究は,臨床CDI単離体における薬剤耐性傾向のモニタリングの重要性を強調しています.
- CDIの効果的な治療戦略を維持するには,継続的な監視が不可欠です.
関連する概念動画
Drugs for Treatment of Diarrhea-Predominant IBS
1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Drugs for Treatment of Ulcerative Colitis in IBD
721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
Antimicrobial Effectiveness
2.3K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
2.3K


